Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELABNASDAQ:GLMDNASDAQ:OTICNASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELABPMGC$2.26-2.2%$2.27$1.95▼$839.86$3.18M0.13384,173 shs56,768 shsGLMDGalmed Pharmaceuticals$1.81-0.3%$1.51$1.15▼$23.80$2.99M0.61.33 million shs110,435 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/APRFXPainReform$1.43+2.4%$1.89$1.25▼$16.63$2.82M0.561.45 million shs14,291 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELABPMGC-2.16%+4.15%+5.61%-47.20%-99.72%GLMDGalmed Pharmaceuticals-0.28%+0.84%+21.96%+34.70%-48.13%OTICOtonomy0.00%0.00%0.00%0.00%0.00%PRFXPainReform+2.43%-1.10%-29.01%-31.39%-21.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELABPMGC0.0833 of 5 stars0.02.00.00.00.00.00.6GLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/APRFXPainReform0.7608 of 5 stars0.04.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELABPMGC 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/AOTICOtonomy 0.00N/AN/AN/APRFXPainReform 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest OTIC, GLMD, ELAB, and PRFX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELABPMGC$1.71M1.82N/AN/A$11.53 per share0.20GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01PRFXPainReformN/AN/AN/AN/A$2.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELABPMGC-$6.25M-$433.87N/A∞N/AN/A-77.80%-59.17%8/13/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%8/26/2025 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/APRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/AN/ALatest OTIC, GLMD, ELAB, and PRFX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/14/2025Q1 2025ELABPMGCN/A-$2.90N/A-$2.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELABPMGCN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELABPMGCN/A8.978.97GLMDGalmed PharmaceuticalsN/A9.029.02OTICOtonomyN/A1.741.74PRFXPainReformN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELABPMGC22.22%GLMDGalmed Pharmaceuticals76.14%OTICOtonomy41.23%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipELABPMGC0.60%GLMDGalmed Pharmaceuticals19.80%OTICOtonomy1.09%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELABPMGC181.38 million1.37 millionN/AGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionablePRFXPainReform42.01 million1.32 millionNot OptionableOTIC, GLMD, ELAB, and PRFX HeadlinesRecent News About These CompaniesBlade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software SalesMay 27, 2025 | prnewswire.comPainReform Ltd.May 12, 2025 | barrons.comPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar ProjectsMay 7, 2025 | finance.yahoo.comPainReform Ltd. Launches Strategic Pilot Program with Econergy Renewable Energy Ltd. to Optimize Solar Energy Production using DeepSolar™ PlatformMay 7, 2025 | quiverquant.comQPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar ProjectsMay 7, 2025 | globenewswire.comPainReform Regains Nasdaq Compliance as of April 16, 2025April 17, 2025 | tipranks.comPainReform announces expansion into SEM sectorApril 10, 2025 | markets.businessinsider.comPainReform Shareholders Approve Key Proposals at April MeetingApril 10, 2025 | tipranks.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | finance.yahoo.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Ltd: PainReform Provides Year-End Business UpdateApril 8, 2025 | finanznachrichten.dePainReform says shareholder equity now exceeds required thresholdApril 8, 2025 | markets.businessinsider.comPainReform Expands into Clean Energy with DeepSolar AcquisitionApril 7, 2025 | tipranks.comPainReform Provides Year-End Business UpdateApril 7, 2025 | globenewswire.comPainReform’s Shareholder Meeting Adjourned Due to Lack of QuorumApril 3, 2025 | tipranks.comPainReform acquires AI solar analytics firm DeepSolarMarch 7, 2025 | uk.investing.comPainReform Ltd: PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar AnalyticsMarch 5, 2025 | finanznachrichten.dePainReform completes acquisition of DeepSolarMarch 5, 2025 | markets.businessinsider.comPainReform Ltd. Completes Acquisition of DeepSolar, Expanding into Clean Energy SectorMarch 5, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeAnalyst Sees Meta Hitting $800: What May Lead Shares to New HighsBy Leo Miller | June 24, 2025View Analyst Sees Meta Hitting $800: What May Lead Shares to New HighsOTIC, GLMD, ELAB, and PRFX Company DescriptionsPMGC NASDAQ:ELAB$2.26 -0.05 (-2.16%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$2.26 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Galmed Pharmaceuticals NASDAQ:GLMD$1.80 -0.01 (-0.28%) Closing price 07/3/2025 03:40 PM EasternExtended Trading$1.82 +0.02 (+0.83%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.PainReform NASDAQ:PRFX$1.43 +0.03 (+2.43%) As of 07/3/2025 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
